遭媒體質疑 健帆生物(300529.SZ)一度大跌近10%
格隆匯12月29日丨健帆生物(300529.SZ)盤初一度大跌9.95%,目前跌幅收窄至4%以內,最新市值逼近550億元。有媒體發文《 <自然> 雜誌用一篇“打臉專用文”,暴擊了健帆生物用“誤導性陳述”編造的600億市值謊言》,質疑健帆生物的一次性使用血液灌流器產品及血液灌流技術在新冠肺炎重危患者救治中的有效性等。健帆生物今早發佈澄清公吿稱,公司不存在市值風雲文章中所提及的誤導性陳述行為,該篇報道以斷章取義、移花接木的手法惡意攻擊公司,企圖誤導投資者,用心險惡、手法卑劣。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.